KURA ONCOLOGY INC (KURA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:KURA • US50127T1097

8.23 USD
-0.04 (-0.48%)
At close: Feb 3, 2026
8.23 USD
0 (0%)
After Hours: 2/3/2026, 8:28:30 PM
Fundamental Rating

3

Taking everything into account, KURA scores 3 out of 10 in our fundamental rating. KURA was compared to 524 industry peers in the Biotechnology industry. While KURA seems to be doing ok healthwise, there are quite some concerns on its profitability. KURA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year KURA has reported negative net income.
  • In the past year KURA had a positive cash flow from operations.
  • KURA had negative earnings in each of the past 5 years.
  • KURA had negative operating cash flow in 4 of the past 5 years.
KURA Yearly Net Income VS EBIT VS OCF VS FCFKURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • The Return On Assets of KURA (-33.40%) is better than 64.12% of its industry peers.
  • KURA's Return On Equity of -89.42% is in line compared to the rest of the industry. KURA outperforms 48.85% of its industry peers.
Industry RankSector Rank
ROA -33.4%
ROE -89.42%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-24.99%
ROE(3y)-37.6%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
KURA Yearly ROA, ROE, ROICKURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • KURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KURA Yearly Profit, Operating, Gross MarginsKURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

  • KURA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • KURA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for KURA has been increased compared to 5 years ago.
  • The debt/assets ratio for KURA has been reduced compared to a year ago.
KURA Yearly Shares OutstandingKURA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KURA Yearly Total Debt VS Total AssetsKURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • KURA has an Altman-Z score of -1.43. This is a bad value and indicates that KURA is not financially healthy and even has some risk of bankruptcy.
  • KURA has a Altman-Z score of -1.43. This is comparable to the rest of the industry: KURA outperforms 54.39% of its industry peers.
  • The Debt to FCF ratio of KURA is 0.12, which is an excellent value as it means it would take KURA, only 0.12 years of fcf income to pay off all of its debts.
  • KURA has a better Debt to FCF ratio (0.12) than 95.99% of its industry peers.
  • KURA has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • KURA has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: KURA outperforms 43.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Altman-Z -1.43
ROIC/WACCN/A
WACC8.93%
KURA Yearly LT Debt VS Equity VS FCFKURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • KURA has a Current Ratio of 5.12. This indicates that KURA is financially healthy and has no problem in meeting its short term obligations.
  • KURA has a Current ratio (5.12) which is in line with its industry peers.
  • A Quick Ratio of 5.12 indicates that KURA has no problem at all paying its short term obligations.
  • KURA has a Quick ratio (5.12) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.12
Quick Ratio 5.12
KURA Yearly Current Assets VS Current LiabilitesKURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

  • The earnings per share for KURA have decreased by -5.08% in the last year.
EPS 1Y (TTM)-5.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, KURA will show a very strong growth in Earnings Per Share. The EPS will grow by 22.38% on average per year.
  • KURA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 144.17% yearly.
EPS Next Y-38.22%
EPS Next 2Y-17.48%
EPS Next 3Y-9.42%
EPS Next 5Y22.38%
Revenue Next Year1072.9%
Revenue Next 2Y354.99%
Revenue Next 3Y181.99%
Revenue Next 5Y144.17%

3.3 Evolution

KURA Yearly Revenue VS EstimatesKURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
KURA Yearly EPS VS EstimatesKURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • KURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KURA Price Earnings VS Forward Price EarningsKURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of KURA indicates a rather cheap valuation: KURA is cheaper than 99.05% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.62
EV/EBITDA N/A
KURA Per share dataKURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • KURA's earnings are expected to decrease with -9.42% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.48%
EPS Next 3Y-9.42%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for KURA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

KURA ONCOLOGY INC

NASDAQ:KURA (2/3/2026, 8:28:30 PM)

After market: 8.23 0 (0%)

8.23

-0.04 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-24
Inst Owners96.89%
Inst Owner Change0.73%
Ins Owners2.16%
Ins Owner Change14.52%
Market Cap716.17M
Revenue(TTM)104.03M
Net Income(TTM)-216.88M
Analysts82.86
Price Target33.2 (303.4%)
Short Float %14.57%
Short Ratio8.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.03%
Min EPS beat(2)-60.23%
Max EPS beat(2)2.17%
EPS beat(4)2
Avg EPS beat(4)-14.36%
Min EPS beat(4)-65.56%
Max EPS beat(4)66.19%
EPS beat(8)5
Avg EPS beat(8)-6.44%
EPS beat(12)9
Avg EPS beat(12)-0.78%
EPS beat(16)13
Avg EPS beat(16)0.98%
Revenue beat(2)0
Avg Revenue beat(2)-54.91%
Min Revenue beat(2)-59.12%
Max Revenue beat(2)-50.69%
Revenue beat(4)2
Avg Revenue beat(4)105.75%
Min Revenue beat(4)-59.12%
Max Revenue beat(4)521.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.38%
PT rev (3m)20.54%
EPS NQ rev (1m)-64.52%
EPS NQ rev (3m)-107.48%
EPS NY rev (1m)-5.08%
EPS NY rev (3m)-10.13%
Revenue NQ rev (1m)-34.26%
Revenue NQ rev (3m)-15.92%
Revenue NY rev (1m)-20.76%
Revenue NY rev (3m)11.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.88
P/FCF 8.62
P/OCF 8.16
P/B 2.95
P/tB 2.95
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-2.8
Fwd EYN/A
FCF(TTM)0.96
FCFY11.6%
OCF(TTM)1.01
OCFY12.26%
SpS1.2
BVpS2.79
TBVpS2.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.4%
ROE -89.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 79.89%
ROA(3y)-28.89%
ROA(5y)-24.99%
ROE(3y)-37.6%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Debt/EBITDA N/A
Cap/Depr 562.91%
Cap/Sales 4.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.12
Quick Ratio 5.12
Altman-Z -1.43
F-Score6
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)52.78%
Cap/Depr(5y)301.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.92%
EPS Next Y-38.22%
EPS Next 2Y-17.48%
EPS Next 3Y-9.42%
EPS Next 5Y22.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1072.9%
Revenue Next 2Y354.99%
Revenue Next 3Y181.99%
Revenue Next 5Y144.17%
EBIT growth 1Y-10.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.45%
EBIT Next 3Y-10.28%
EBIT Next 5Y1.83%
FCF growth 1Y170.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y175.01%
OCF growth 3YN/A
OCF growth 5YN/A

KURA ONCOLOGY INC / KURA FAQ

What is the ChartMill fundamental rating of KURA ONCOLOGY INC (KURA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KURA.


What is the valuation status of KURA ONCOLOGY INC (KURA) stock?

ChartMill assigns a valuation rating of 2 / 10 to KURA ONCOLOGY INC (KURA). This can be considered as Overvalued.


Can you provide the profitability details for KURA ONCOLOGY INC?

KURA ONCOLOGY INC (KURA) has a profitability rating of 1 / 10.


How financially healthy is KURA ONCOLOGY INC?

The financial health rating of KURA ONCOLOGY INC (KURA) is 6 / 10.